Drug intelligence / Profile preview

CS28599

Development stage: Preclinical
Lead developer: Akeso
Modality: Small Molecules

Overview

CS28599 is a preclinical-stage small molecule inhibitor developed by Chipscreen Biosciences. It specifically targets the KRAS G12D mutation, which is a common oncogenic driver in various solid tumors, including pancreatic, colorectal, and lung cancers. By inhibiting the KRAS G12D mutant protein, CS28599 aims to disrupt downstream signaling pathways that promote tumor cell proliferation and survival.

Targets

KRASG12D (Kirsten rat sarcoma viral oncogene homolog (KRAS) G12D mutant)

Beyond the preview

Go deeper on CS28599.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CS28599.

Explore the full profile